Institution
Albert Schweitzer Hospital
Healthcare•Lambaréné, Gabon•
About: Albert Schweitzer Hospital is a healthcare organization based out in Lambaréné, Gabon. It is known for research contribution in the topics: Population & Plasmodium falciparum. The organization has 1029 authors who have published 1568 publications receiving 43581 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: BPD/DS provided substantial weight loss after LAGB failure and reduced the incidence of obesity-related co-morbidities during a 3-year period of follow-up.
12 citations
••
01 Jan 2019TL;DR: On 18 October 2018, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the inactivated cell-based quadrivalent influenza vaccine Flucelvax Tetra for the use in adults and in children aged 9 years and above.
Abstract: On 18 October 2018, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the inactivated cell-based quadrivalent influenza vaccine Flucelvax Tetra for the use in adults and in children aged 9 years and above.1 Influenza is a major cause of illness and mortality worldwide. Clinical attack rates often range from 10% to 20% in the general community during epidemics and can be as high as 50% in closed populations, such as schools or nursing homes.2 According to the WHO, influenza causes annually three to five million cases of severe respiratory tract infections and is estimated to result in 290 000–650 000 respiratory deaths per year globally.3 During pandemics, such as the 1918 pandemic, the death toll has been estimated to be as high as 40 million.2 Vaccination against influenza does not confer complete protection but it has been consistently shown to have an important impact on morbidity and has therefor become an important public health intervention to protect vulnerable patient populations. Since many years several commercial influenza vaccine products are available in Europe, so that one have to ask what are the advantages of the latest registered influenza vaccine …
12 citations
••
TL;DR: In this paper, the authors performed an external audit of consecutive series of all transanal total mesorectal excision (TaTME) procedures in six centres in the Netherlands and found a high local recurrence rate after implementation of TaTME which lowers to an acceptable rate (3.4%) when experience increases.
Abstract: Aim: Transanal total mesorectal excision (TaTME) has been suggested as a potential solution for the resection of challenging mid and low rectal cancer. This relatively complex procedure has been implemented in many centres over the last years, despite the absence of long-term safety data. Recently, concern has arisen because of an increase in local recurrence in the implementation phase. The aim of this study was to assess the correlation between accumulated experience and local recurrences. Method: An independent clinical researcher performed an external audit of consecutive series of all TaTME procedures in six centres in the Netherlands. Kaplan–Meier estimated local recurrence rates were calculated and multivariate Cox proportional hazards regression analysis performed to assess risk factors for local recurrence. Primary outcome was the local recurrence rate in the initial implementation (cases 1–10), continued adoption (cases 11-40) and prolonged experience (case 41 onward). Results: Six hundred and twenty-four consecutive patients underwent TaTME for rectal cancer with a median follow-up of 27 months (range 1–82 months). The estimated 2- and 3-year local recurrence rates were 4.6% and 6.6%, respectively. Cox proportional hazards regression revealed procedural experience to be an independent factor in multivariate analysis next to advanced stage (ycMRF+, pT3-4, pN+) and pelvic sepsis. Corrected analysis projected the 3-year local recurrence rates to be 9.7%, 3.3% and 3.5% for the implementation, continued adoption and prolonged experience cohorts, respectively. Conclusion: This multicentre study shows a high local recurrence rate (12.5%) after implementation of TaTME which lowers to an acceptable rate (3.4%) when experience increases. Therefore, intensified proctoring and further precautions must be implemented to reduce the unacceptably high risk of local recurrence at units starting this technique.
12 citations
••
TL;DR: Significant hospital variation in the use of preoperative chemotherapy for CRLM was present in the Netherlands and no association between postoperative outcomes and use ofPreoperative chemotherapy was found.
Abstract: Introduction: Definitions regarding resectability and hence indications for preoperative chemotherapy vary. Use of preoperative chemotherapy may influence postoperative outcomes. This study aimed to assess the variation in use of preoperative chemotherapy for CRLM and related postoperative outcomes in the Netherlands. Materials and methods: All patients who underwent liver resection for CRLM in the Netherlands between 2014 and 2018 were included from a national database. Case-mix factors contributing to the use of preoperative chemotherapy, hospital variation and postoperative outcomes were assessed using multivariable logistic regression. Postoperative outcomes were postoperative complicated course (PCC), 30-day morbidity and 30-day mortality. Results: In total, 4469 patients were included of whom 1314 patients received preoperative chemotherapy and 3155 patients did not. Patients receiving chemotherapy were significantly younger (mean age (+SD) 66.3 (10.4) versus 63.2 (10.2) p < 0.001) and had less comorbidity (Charlson scores 2+ (24% versus 29%, p = 0.010). Unadjusted hospital variation concerning administration of preoperative chemotherapy ranged between 2% and 55%. After adjusting for case-mix factors, three hospitals administered significantly more preoperative chemotherapy than expected and six administered significantly less preoperative chemotherapy than expected. PCC was 12.1%, 30-day morbidity was 8.8% and 30-day mortality was 1.5%. No association between preoperative chemotherapy and PCC (OR 1.24, 0.98–1.55, p = 0.065), 30-day morbidity (OR 1.05, 0.81–1.39, p = 0.703) or with 30-day mortality (OR 1.22, 0.75–2.09, p = 0.467) was found. Conclusion: Significant hospital variation in the use of preoperative chemotherapy for CRLM was present in the Netherlands. No association between postoperative outcomes and use of preoperative chemotherapy was found.
12 citations
••
TL;DR: The objective was to assess the 2‐year clinical performance of three drug‐eluting stents in all‐comer patients with severely calcified coronary lesions.
Abstract: Objective The objective was to assess the 2-year clinical performance of three drug-eluting stents in all-comer patients with severely calcified coronary lesions. Background Severe lesion calcification increases cardiovascular event risk after coronary stenting, but there is a lack of data on the clinical outcome of all-comers with severely calcified lesions who were treated with more recently introduced drug-eluting stents. Methods The BIO-RESORT trial (clinicaltrials.gov: NCT01674803) randomly assigned 3,514 all-comer patients to biodegradable polymer Synergy everolimus-eluting stents (EES) or Orsiro sirolimus-eluting stents (SES), versus durable polymer Resolute Integrity zotarolimus-eluting stents (ZES). In a post hoc analysis, we assessed 783 patients (22.3%) with at least one severely calcified target lesion. Results At 2-year follow-up (available in 99% of patients), the main composite endpoint target vessel failure occurred in 19/252 (7.6%) of the EES and in 33/265 (12.6%) of the ZES-treated patients (p = .07). Target vessel failure occurred in 24/266 (9.1%) of the SES-treated patients (vs. ZES: p = .21). There was a difference in target vessel revascularization, which was required in EES in 6/252 (2.4%) patients and in ZES in 20/265 (7.7%) patients (p = .01); the target vessel revascularization rate in SES was 9/266 (3.4%, vs. ZES: p = .04). Multivariate analysis showed that implantation of EES, but not SES, was independently associated with lower target vessel revascularization rates than in ZES. Conclusions In BIO-RESORT participants with severely calcified target lesions, treatment with EES was associated with a lower 2-year target vessel revascularization rate than treatment with ZES.
12 citations
Authors
Showing all 1029 results
Name | H-index | Papers | Citations |
---|---|---|---|
Peter G. Kremsner | 87 | 739 | 32544 |
Andreas Voss | 83 | 757 | 28426 |
Sandrine Florquin | 72 | 372 | 18406 |
Maria Yazdanbakhsh | 68 | 322 | 19397 |
Sanjeev Krishna | 67 | 285 | 18547 |
Martin P. Grobusch | 57 | 497 | 14024 |
Adrian J. F. Luty | 53 | 114 | 7094 |
Dirk G. Struijk | 53 | 201 | 9182 |
T. Peter Kingham | 52 | 298 | 8905 |
Michiel G. H. Betjes | 51 | 229 | 8689 |
Benjamin Mordmüller | 47 | 195 | 8319 |
Saadou Issifou | 45 | 109 | 6458 |
Steffen Borrmann | 44 | 104 | 7736 |
Bertrand Lell | 42 | 135 | 6582 |
Ayola A. Adegnika | 39 | 166 | 5433 |